Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A2β in prostate cancer cells

Prostate

Volumn 69, Issue 12, 2009, Pages 1270-1280

  Nicotera, Thomas M ^a   Schuster, David P ^b   Bourhim, Mustapha ^a   Chadha, Kailash ^a   Klaich, Gary ^c   Corral, David A ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b D'YOUVILLE COLLEGE   (United States)

^c Triangle Urological Group   (United States)

Author keywords

Phospholipase A2; Prostate specific antigen; Secretion; Survival

Indexed keywords

ANDROGEN; CALCIUM INDEPENDENT PHOSPHOLIPASE A2; CALCIUM INDEPENDENT PHOSPHOLIPASE A2 BETA; MESSENGER RNA; PHOSPHOLIPASE A2; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

APOPTOSIS; CALCIUM; CELL LINE, TUMOR; CELL SURVIVAL; EPITHELIAL CELLS; GENE EXPRESSION; GROUP IV PHOSPHOLIPASES A2; HUMANS; ISOENZYMES; MALE; NAPHTHALENES; PHOSPHODIESTERASE INHIBITORS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PYRONES; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 67650860256     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20968     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA: Cancer J Clin 2007;57(1):43-66.
2. Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145(5):907-923.
3. Denmeade SR, Isaacs JT. The role of prostate-specific antigen in the clinical evaluation of prostatic disease. BJU Int D 2004;93 (Suppl 1):10-15.
4. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM, Bueschen AJ, Lowe BA. Bilateral orchiectomy with or withoutflutamide for metastatic prostate cancer. NEngl J Med 1998;339(15):1036-1042.
5. Nicotera TM, Bourhim M, Schuster DP, Mohler JL, Godoy A, Chadha K. submitted for publication.
6. Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J, Han R, Ma T, Kuo HC, Chang C. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res 2008;68(17):7110-7119.
7. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93(22):1687-1697.
8. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-39.
9. Cohen RJ, McNeal JE, Edgar SG, Robertson T, Dawkins HJ. Characterization of cytoplasmic secretory granules (PSG), in prostatic epithelium and their transformation-induced loss in dysplasia and adenocarcinoma. Hum Pathol 1998;29(12):1488-1494.
10. Lilja H.A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76(5): 1899-1903.
11. Ishida E, Nakamura M, Shimada K, Kishi M, Nakaoka S, Konishi N. Distribution and secretory pathways of prostate specific antigen, alpha1-antichymotrypsin and prostate secretory granules in prostate cancers. Pathol Int 2003;53(7):415-421.
12. Cohen RJ, Beales MP, McNeal JE. Prostate secretory granules in normal and neoplastic prostate glands: A diagnostic aid to needle biopsy. Hum Pathol 2000;31(12):1515-1519.
13. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997;18(6):1215-1223.
14. Gau JT, Salter RD, Krill D, Grove ML, Becich MJ. The biosynthesis and secretion of prostate-specific antigen in LNCaP cells. Cancer Res 1997;57(17):3830-3834.
15. Young CY, Andrews PE, Tindall DJ. Expression and androgenic regulation of human prostate-specific kallikreins. J Androl 1995; 16(2):97-99.
16. Johnson JL, Ellis BA, Noack D, Seabra MC, Catz SD. The Rab27a-binding protein, JFC1, regulates androgen-dependent secretion of prostate-specific antigen and prostatic-specific acid phosphatase. Biochem J 2005;391(3):699-710.
17. Ma Z, Ramanadham S, Wohltmann M, Bohrer A, Hsu FF, Turk J. Studies of insulin secretory responses and of arachidonic acid incorporation into phospholipids of stably transfected insulinoma cells that overexpress group VIA phospholipase A2 (iPLA2beta) indicate a signaling rather than a housekeeping role for iPLA2beta. J Biol Chem 2001;276(16):13198-13208.
18. Whitacre DC, Chauhan S, Davis T, Gordon D, Cress AE, Miesfeld RL. Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ 2002;13(1):1-11.
19. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992;263 (2 Pt 2):F181-F191.
20. 2 superfamily and its group numbering system. Biochim Biophys Acta 2006; 1761:1246-1259.
21. Tang J, Kriz RW, Wolfman N, Shaffer M, Seehra J, Jones SS. A novel cytosolic calcium-independent phospholipase A2 contains eight ankyrin motifs. J Biol Chem 1997;272(13):8567-8575.
22. Balboa MA, Balsinde J, Jones SS, Dennis EA. Identity between the Ca2+-independent phospholipase A2 enzymes from P388D1 macrophages and Chinese hamster ovary cells. J BiolChem1997; 272(13):8576-8580.
23. Ma Z, Ramanadham S, Kempe K, Chi XS, Ladenson J, Turk J. Pancreatic islets express a Ca2+-independent phospholipase A2 enzyme that contains a repeated structural motif homologous to the integral membrane protein binding domain of ankyrin. J Biol Chem 1997;272(17):11118-11127.
24. Jenkins CM, Wolf MJ, Mancuso DJ, Gross RW. Identification of the calmodulin-binding domain of recombinant calciumindependent phospholipase A2beta. Implications for structure and function. J Biol Chem 2001;276(10):7129-7135.
25. Larsson PK, Claesson HE, Kennedy BP. Multiple splice variants of the human calcium-independent phospholipase A2 and their effect on enzyme activity. J Biol Chem 1998;273(1):207-214.
26. Ma Z, Turk J. The molecular biology of the group VIA Ca2+-independent phospholipase A2. Prog Nucleic Acid Res Mol Biol 2001;67:1-33.
27. Ma Z, Bohrer A, Wohltmann M, Ramanadham S, Hsu FF, Turk J. Studies of phospholipid metabolism, proliferation, and secretion of stably transfected insulinoma cells that overexpress group VIA phospholipase A2. Lipids 2001;36(7):689-700.
28. Takuma T, Ichida T. Role of Ca2+-independent phospholipase A2 in exocytosis of amylase from parotid acinar cells. J Biochem (Tokyo) 1997;121(6):1018-1024.
29. Alzola E, Perez-Etxebarria A, Kabre E, et al. Activation by P2X7 agonists of two phospholipases A2 (PLA2) in ductal cells of rat submandibular gland. Coupling of the calcium-independent PLA2 with kallikrein secretion. J Biol Chem 1998;273(46):30208-30217.
30. Balboa MA, Saez Y, Balsinde J. Calcium-independent phospholipase A2 is required for lysozyme secretion in U937 promonocytes. J Immunol 2003;170(10):5276-5280.
31. Ma Z, Zhang S, Turk J, Ramanadham S. Stimulation of insulin secretion and associated nuclear accumulation of iPLA(2)beta in INS-1 insulinoma cells. Am J Physiol Endocrinol Metab 2002;282(4):E820-833.
32. Bao S, Bohrer A, Ramanadham S, Jin W, Zhang S, Turk J. Effects of stable suppression of Group VIA phospholipase A2 expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells. J Biol Chem 2006;281(1):187-198.
33. Bindukumar B, Kawinski E, Cherrin C, Gambino LM, Nair MPN, Schwartz SA, Chadha KC. Two step procedure for purification of enzymatically active prostate-specific antigen from seminal plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 813(1-2):113-120.
34. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82(13):1107-1112.
35. Reynolds LJ, Hughes LL, Yu L, Dennis EA. 1-Hexadecyl-2-arachidonoylthio- 2-deoxy-sn-glycero-3-phosphorylcholine as a substrate for the microtiterplate assay of human cytosolic phospholipase A2. Anal Biochem 1994;217(1):25-32.
36. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29(9):e45.
37. Sun XY, Donald SP, Phang JM. Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis 2001;22(11):1775-1780.
38. Fraumeni JF, Hoover RN, Devesa SS, Kinlen JL. Epidemiology of cancer. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology. Philadelphia, PA: Lippincott; 1989. pp. 196-209.
39. Mullin JM. Epithelial barriers, compartmentation, and cancer. Science's Stke 2004(216): pe2. 36.
40. Vermeer PD, Einwalter LA, Moninger TO, Rokhlina T, Kern JA, Zabner J, Welsh MJ. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature 2003; 422(6929):322-326.
41. Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FF, Lin MF. ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCa P C-8 cells. Oncogene 2003;22:781-786.
42. Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Human Pathol 2007;38(4):564-569.
43. Zheng JY, Yu D, Foroohar M, Ko E, Chan J, Kim N, Chiu R, Pang S. Regulation of the expression of the prostate-specific antigen by claudin-7. J Membr Biol 2003;194(3):187-197.
44. Gurova KV, Roklin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E, Gudkov AV. Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene 2002;21(1):153-157.
45. Chen H, Nandi AK, Li X, Bieberich CJ. NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res 2002;62(2):338-340.
46. Corey E, Brown LG, Corey MJ, Buhler KR, Vessella RL. LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen. Prostate 1998;35(2):135-143.
47. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001;48(1):1-6.
48. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999;59(12):2891- 2897.
49. Yang L, Xie S, Jamaluddin S, Altuwaijri S, Ni J, Kim E, Chen YT, Hu YC, Wang L, Chuang KH, Wu CT, Chang C. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/ Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 2005; 280(39):33558-33565.
50. Gao J, Arnold JT, Isaacs JT. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 2001;61(13):5038-5044.